Focus: Cumberland Pharmaceuticals is a small-molecule pharmaceutical company based in Nashville, TN specializing in neurology and hospital-based therapeutics. The company is heavily dependent on a single product, SANCUSO, which generates 90% of revenue.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cumberland Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (90% of company revenue) but approaching loss of exclusivity with no LOE date specified, creating critical commercial vulnerability.
Help build intelligence for Cumberland Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cumberland Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest marketed product losing exclusivity in 2027; minimal revenue contribution and strong cliff risk.
Generic antihistamine in pre-launch phase; unlikely to be material revenue contributor.
Specialty intravenous agent with active shortage status (unavailable) and declining revenue trajectory.
Intravenous NSAID in peak commercial phase with exclusivity extending to 2032; multiple expansion trials ongoing.
Duplicate listing of VAPRISOL; vasoactive agent approaching LOE with limited current revenue.
Triple-therapy combination product approaching exclusivity loss; minimal current market presence.
Life-critical antidote product in peak phase with exclusivity to 2032; Phase 3 enhanced formulation (Acetadote EF) in development.
Generic osmotic laxative already past loss of exclusivity; minimal strategic value.
4 discontinued, 1 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Active drug shortage (Conivaptan Hydrochloride Injection unavailable) indicates manufacturing or supply-chain distress; no recent layoff data available but single-product revenue concentration and patent cliffs suggest elevated restructuring risk.